Someone you know may be interested in learning more about PERTZYE® (pancrelipase) and EPI due to cystic fibrosis (CF). Simply complete all fields below and then submit to share this information.
Dear [COLLEAGUE'S NAME],
I thought you would be interested in a treatment called PERTZYE® (pancrelipase). It is indicated for the treatment of exocrine pancreatic insufficiency due to cystic fibrosis (CF) or other conditions.
PERTZYE microspheres are formulated to contain pancreatic enzymes buffered with bicarbonate designed to simulate normal pancreatic digestive function in CF patients with EPI.1-4
You can learn more about this treatment at www.pertzyecares.com.
Important Safety Information
Fibrosing colonopathy is associated with high-dose use of pancreatic enzyme replacement. Exercise caution when doses of PERTZYE® (pancrelipase) exceed 2,500 lipase units/kg body weight per meal (or greater than 10,000 lipase units/kg body weight per day).
To avoid irritation of oral mucosa, do not chew PERTZYE or retain in the mouth.
Hyperuricemia may develop. Consider monitoring uric acid levels in patients with hyperuricemia, gout, or renal impairment.
There is theoretical risk of viral transmission with all pancreatic enzyme products including PERTZYE.
Exercise caution when administering pancrelipase to a patient with a known allergy to proteins of porcine origin.
Most common adverse reactions (≥ 10%) are: diarrhea, dyspepsia, and cough.
Indication
PERTZYE is indicated for the treatment of exocrine pancreatic insufficiency due to cystic fibrosis or other conditions.
Please click here for Full Prescribing Information and Medication Guide.
References: 1. Ishiguro H, Steward MC, Naruse S, et al. CFTR functions as a bicarbonate channel in pancreatic duct cells. J Gen Physiol. 2009;133(3):315-326. 2. PERTZYE (pancrelipase) Prescribing Information. Digestive Care, Inc., Bethlehem, PA: July 2017. 3. Borowitz DS, Grand RJ, Durie PR, Consensus Committee. Use of pancreatic enzyme supplements for patients with cystic fibrosis in the context of fibrosing colonopathy. J Pediatr. 1995;127(5):681-684. 4. Manual of Clinical Enzyme Measurements. Freehold, NJ: Worthington Biomedical Corporation; 1972:1-56.
